Other Events ·
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™…
TAKTakeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults. This marks the first approval of a medicine to treat the underlying cause of the disease holistically rather than targeting individual symptoms. The approval is based on Phase 3 clinical trials demonstrating significant improvements in excessive daytime sleepiness, cataplexy, and quality of life. Takeda expects ORZEYFUL to be available following completion of the Drug Enforcement Administration scheduling process, which is anticipated within 90 days. The company stated that this approval is not expected to have a significant impact on its full-year consolidated financial forecast for the fiscal year ending March 31, 2027. Takeda operates in the pharmaceutical and biotechnology industry, focusing on discovering and delivering life-transforming treatments across various therapeutic areas.